Diagnostic and Interventional Cardiology DAIC

Diagnostic and Interventional Cardiology (DAIC) is a magazine that reaches more than 25,000 healthcare professionals in cardiology, interventional cardiology and cath labs across the United States. These influential buying team members rely on DAIC's award-winning editorial content and comparison charts as a unique research tool for specifying, recommending and approving technology/device purchases.

A new American Heart Association scientific statement highlights the need for more data and research about sex differences in the use and response to mechanical clot removal for acute ischemic stroke and suggests a clear differentiation between sex and gender in future research

News | Stroke

More Data Needed on Stroke Treatment and Outcomes by Gender

June 14, 2022 — A new American Heart Association scientific statement highlights the need for more data and research ...

June 14, 2022

Individuals with diabetes display a substantially increased risk of disease in left-sided heart valves compared to controls without diabetes, a comprehensive register study at the University of Gothenburg shows.

News | Heart Failure

New Light on Association Between Diabetes and Heart Valve Disease

June 10, 2022 — Individuals with diabetes display a substantially increased risk of disease in left-sided heart valves c ...

June 10, 2022

product comparison charts for cardiology and health IT systems

Feature | Cardiovascular Business

Cardiology Product Comparison Charts Aid in Buying Decisions

Diagnostic and Interventional Cardiology (DAIC) maintains more than 50 comparison charts of product specifications from ...

June 09, 2022

The Hollywood, Fla. facility - home to the Memorial Cardiac and Vascular Institute - becomes just the fourth hospital in the U.S. to earn advanced certification from the American College of Cardiology

News | Heart Failure

Memorial Regional Hospital Earns Advanced Heart Failure Accreditation

June 9, 2022 — Memorial Regional Hospital recently entered elite company, becoming just the fourth hospital in the ...

June 09, 2022

New results demonstrate MitraClip transcatheter edge-to-edge repair (TEER) is effective at treating leaky valves in people with secondary mitral regurgitation (MR)

News | Structural Heart

Late-Breaking Data Reinforce Broad Range of Patients Benefit from Abbott's Mitral and Tricuspid Heart Valve Devices

June 9, 2022 — Abbott announced late-breaking data for MitraClip, the world's first transcatheter edge-to-edge repair ...

June 09, 2022

The U.S. Food and Drug Administration (FDA) has issued a release stating that Medtronic is recalling the HVAD Pump Implant Kit due to a pump weld defect.

News | Ventricular Assist Devices (VAD)

Medtronic Recalls HVAD Pump Implant Kit for Pump Weld Defect

June 8, 2022 — The U.S. Food and Drug Administration (FDA) has issued a release stating that Medtronic is recalling the ...

June 08, 2022

News | Cardiovascular Business

National Leader in Cardiac Surgery Quality and Research Joins Cedars-Sinai

June 7, 2022 — Michael Bowdish, MD, MS, a national leader in cardiac surgery and among a handful of cardiac surgeons ...

June 07, 2022

Less than 1 in 10 were on any non-statin lipid lowering therapy

News | Heart Failure

Data Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a Statin Were Not On Any Statin

June 3, 3033 — Esperion announced findings from a real-world analysis of more than 400,000 patients at high-risk for ath ...

June 03, 2022

During National CPR & AED Awareness Week 2022, Texas Children's celebrates Garrett Richardson's inspiring story

News | Sudden Cardiac Arrest

Texas Children's Hospital Patient Thriving Today Despite Sudden Cardiac Arrest

June 3, 2022 — Texas Children's Hospital patient Garrett Richardson, 21, is alive today because his quick-thinking ...

June 03, 2022

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death.

News | Stents

FDA Class 1 Recall on iCast Stent for Separation Risk That May Cause Harm

June 2, 2022 — According to the U.S. Food and Drug Administration (FDA), Atrium Medical Corporation is recalling the iCa ...

June 02, 2022

Dr. Jeff Healey is seen implanting a subcutaneous defibrillator in a patient at the Electrophysiology Lab. Image credit: Owen Thomas, Hamilton Health Sciences.

Feature | Cardiovascular Business | By Melinda Taschetta-Millane

DAIC's Top 10 Most-read Content for May

Here is what you and your colleagues found to be most interesting in the field of cardiology during the month of May ...

June 01, 2022

Biofourmis Care, a comprehensive care management platform including virtual multidisciplinary care teams, to be evaluated against in-person care among underserved patients with chronic cardiovascular conditions

News | Cardiovascular Clinical Studies

Biofourmis Selected by ACC as Exclusive Virtual Care Platform to Drive TRANSFORM(3) Study

June 1, 2022 — Biofourmis, a Boston-based global leader in virtual care and digital medicine, announced that its ...

June 01, 2022

Eating low glycaemic index foods promotes a healthier body shape in patients with coronary artery disease, according to a study presented at ACNAP-EuroHeartCare Congress 2022, a scientific congress of the European Society of Cardiology (ESC).

News | ESC

Low Glycaemic Index Diet Helps Heart Patients Lose Weight

June 1, 2022 — Eating low glycaemic index foods promotes a healthier body shape in patients with coronary artery disease ...

June 01, 2022

Recardio Inc., a late stage clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the FDA concurs with Recardio's pivotal Heal-MI Phase 3 trial design with Dutogliptin in Acute Myocardial Infarction

News | Cardiogenic Shock

Recardio and FDA Reach Agreement on Pivotal Phase 3 Trial Design

June 1, 2022 — Recardio's Phase 2 trial results demonstrated the excellent safety profile of its lead drug Dutogliptin ...

June 01, 2022

COMPASS open label extension study results support the long-term use of XARELTO plus aspirin for vascular protection in patients with chronic CAD and/or PAD

News | Cardiovascular Clinical Studies

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition with XARELTO Plus Aspirin in Patients with Coronary Artery Disease, Peripheral Artery Disease

May 31, 2022 — Findings from the XARELTO (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and ...

May 31, 2022